COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03353922
Recruitment Status : Completed
First Posted : November 27, 2017
Last Update Posted : September 4, 2018
Cognitive Research Corporation
Information provided by (Responsible Party):
Neurana Pharmaceuticals, Inc.

Brief Summary:
This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.

Condition or disease Intervention/treatment Phase
Driving Impaired Drug: Cyclobenzaprine 10 Mg Oral Tablet Drug: Placebo Oral Tablet Phase 1

Detailed Description:

This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30 male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times daily), and placebo. Subjects will receive 3 days of each treatment.

Subject participation will be approximately 3 weeks as outpatients with 3 days each week as overnight clinic participants.

In this crossover study, treatment effects will be assessed following the second initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).

Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose on Day 1, subjects will be administered the cognitive test, followed by the driving simulator examination.

On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test and driving examination to assess residual next day effects.

Subjects will repeat cognitive testing and the driving examination on the morning of Day 3, after administration of the AM study medication, to evaluate the cumulative effects of 3 days of dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: multiple-dose 3-way cross-over study
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: subjects are blindfolded to receive oral dose of treatment, matching placebo, or unblinded active control
Primary Purpose: Treatment
Official Title: Driving Simulation Cross-Over Study of Sedative Effects of Tolperisone Compared to Cyclobenzaprine and Placebo
Actual Study Start Date : July 31, 2017
Actual Primary Completion Date : December 6, 2017
Actual Study Completion Date : January 30, 2018

Arm Intervention/treatment
Experimental: Tolperisone HCl 150 mg
150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
Drug: Cyclobenzaprine 10 Mg Oral Tablet
cyclobenzaprine 10 mg tablets
Other Name: Flexeril

Drug: Placebo Oral Tablet
sugar pill
Other Name: tolperisone matching placebo

Placebo Comparator: Placebo Oral Tablet
sugar pills administered by mouth every 8 hours for 3 days
Drug: Cyclobenzaprine 10 Mg Oral Tablet
cyclobenzaprine 10 mg tablets
Other Name: Flexeril

Drug: Placebo Oral Tablet
sugar pill
Other Name: tolperisone matching placebo

Active Comparator: Cyclobenzaprine 10 mg oral tablet
10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
Drug: Placebo Oral Tablet
sugar pill
Other Name: tolperisone matching placebo

Primary Outcome Measures :
  1. Standard Deviation of Lateral Position (SDLP) [ Time Frame: at Tmax on Day 1 ]
    SDLP measured by simulated driving performance using CRCDS-MiniSim,

Secondary Outcome Measures :
  1. SDLP of tolperisone compared to cyclobenzaprine [ Time Frame: at Tmax on Day 1 ]
    SDLP measured by simulated driving performance of tolperisone compared to cyclobenzaprine

  2. Sleepiness Endpoint Karolinska Sleepiness Scale KSS [ Time Frame: at Tmax on Day 1 ]
    assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy

  3. Self-reported readiness to drive [ Time Frame: at Tmax on Day 1 ]
    Subject response to: "Right now do you feel safe to drive?"

  4. Sleepiness Scale VAS [ Time Frame: at Tmax on Day 1 ]
    assessment of self-reported drowsiness where 1 equals not at all sleepy and 9 equals sleepy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. All healthy volunteer subjects must be in general good health based on screening physical examination (defined as the absence of any clinically relevant abnormalities), medical history, 12-lead ECG, and clinical laboratory values (hematology, serum chemistry and urinalysis).
  2. All subjects must be capable of understanding and complying with the protocol and have signed the informed consent document. Female subjects of childbearing potential must sign the Women of Childbearing Potential Addendum to the informed consent form.
  3. Subjects are required to have a body mass index (BMI) of 18 to 32 kg/m2, inclusive, at Screening.
  4. Subject must be able to reliably perform study assessments (i.e., SDLP no higher than 1 standard deviation greater than the mean for normal healthy adults completing the CVDA practice scenario; and number correct on CogScreen Symbol Digit Coding no less than 1 standard deviation below the mean for healthy adults in the 21-55 year age range); demonstrates the ability to understand task instructions (in English), and be physically capable (e.g., adequate manual dexterity, vision, and hearing), cognitively capable and motivated to perform study tasks.
  5. Subject must possess a valid driver's license and be an active driver, and have driven a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.
  6. Subject must also demonstrate simulator sickness questionnaire scores which are not indicative of simulator sickness as defined in the driving simulation operations manual.
  7. Subject must have a regular sleep pattern, not be engaged in shift-work, and in general, have at least 7 hours of sleep each night (bedtime occurs between 21:00 and 24:00 hours).
  8. Subject has a score < 10 on the Epworth Sleepiness Scale (ESS).
  9. Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Subjects who have any clinically significant unstable medical abnormality, chronic disease or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems.
  2. Subjects who test positive at screening for hepatitis B surface antigen, hepatitis C antibody or have a history of a positive result.
  3. Subjects who are known to be seropositive or test positive at Screening for Human immunodeficiency virus (HIV).
  4. Female subjects who are pregnant or lactating.
  5. Subjects who have a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
  6. A history within 2 years of, or current treatment for a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep.
  7. A history of difficulty in falling asleep or staying asleep in the previous 3 months, that is considered clinically significant by the investigator.
  8. Subjects who have a history or diagnosis of any of the following conditions:

    1. Primary or secondary insomnia
    2. Narcolepsy
    3. Cataplexy (familial or idiopathic)
    4. Circadian Rhythm Sleep Disorder
    5. Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and rapid eye movement behavior disorder
    6. Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome)
    7. Periodic Limb Movement Disorder
    8. Restless Legs Syndrome
    9. Primary Hypersomnia
    10. Excessive Daytime Sleepiness (EDS)
    11. Subject has visual or auditory impairment which in the opinion of the investigator would interfere with study related procedures or study conduct.
  9. Subjects expected to use any other medication or dietary supplement to promote sleep including over-the-counter sleep medications, during their participation in the study.
  10. Subjects who have participated in any investigational study within 30 days prior to screening or are currently participating in another clinical trial.
  11. Subjects who have had a recent history (less than 2 years before entering the study) of drug or alcohol abuse, or current positive urine drug screen. Alcohol abuse is defined as current consumption of more than three alcoholic beverages per day.
  12. Subjects who have a history of allergic reaction to tolperisone or cyclobenzaprine or any components of these study medications.
  13. Use of psychoactive prescription or non-prescription medications, psychoactive nutritional supplements or herbal preparations within 2 weeks or 5 half-lives (whichever is longer) of admission to the Clinical Research Unit (CRU) on Day 1.
  14. Presence of a medical or psychiatric condition which could jeopardize the safety of the subject or validity of study results
  15. Subjects who consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day. Excessive amount is defined as greater than 6 servings per day (where 1 serving is approximately equivalent to 120 mg of caffeine).
  16. Subjects who will be working a night shift within 1 week of a visit.
  17. Subject who have traveled across 1 or more time zones (transmeridian travel) in the last 2 weeks prior to randomization or is expected to travel across 1 or more time zones during the study.
  18. Current smoker (>10 cigarettes or eCigarettes, 3 cigars, or 3 pipes per day) and unwilling to refrain from smoking while confined to the CRU for periods of 3 days.
  19. Subjects who have an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
  20. Subjects who are a staff member or relative of a staff member.
  21. Inability or unwillingness to use adequate contraception (as defined in item 10 of the Inclusion Criteria) during and for 1 month following completion of the study.
  22. Has a positive screen for alcohol or other drugs of abuse (amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03353922

Layout table for location information
United States, California
Collaborative Neuroscience Network
Long Beach, California, United States, 92845
United States, Georgia
NeuroTrials Research
Atlanta, Georgia, United States, 30342
Sponsors and Collaborators
Neurana Pharmaceuticals, Inc.
Cognitive Research Corporation
Layout table for investigator information
Principal Investigator: Russell Rosenberg, PhD NeuroTrials Research, Atlanta GA
Principal Investigator: David Walling, PhD Collaborative Neuroscience Network, Garden Grove, CA
Layout table for additonal information
Responsible Party: Neurana Pharmaceuticals, Inc. Identifier: NCT03353922    
Other Study ID Numbers: NR115
First Posted: November 27, 2017    Key Record Dates
Last Update Posted: September 4, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Neurana Pharmaceuticals, Inc.:
cognitive function
Additional relevant MeSH terms:
Layout table for MeSH terms
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
Tranquilizing Agents
Central Nervous System Depressants